BRPI0714667A8 - Conjugado molecular e respectivo uso - Google Patents

Conjugado molecular e respectivo uso

Info

Publication number
BRPI0714667A8
BRPI0714667A8 BRPI0714667A BRPI0714667A BRPI0714667A8 BR PI0714667 A8 BRPI0714667 A8 BR PI0714667A8 BR PI0714667 A BRPI0714667 A BR PI0714667A BR PI0714667 A BRPI0714667 A BR PI0714667A BR PI0714667 A8 BRPI0714667 A8 BR PI0714667A8
Authority
BR
Brazil
Prior art keywords
photosensitizer
vector
conjugates
ethylene glycol
glycol units
Prior art date
Application number
BRPI0714667A
Other languages
English (en)
Inventor
E Nifantiev Nikolay
Gitter Burkhard
V Yashunsky Dmitry
Original Assignee
Ceramoptec Ind Inc
Biolitec Pharma Marketing Ltd
Biolitec Unternehmensbeteiligungs Ii Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Ceramoptec Ind Inc, Biolitec Pharma Marketing Ltd, Biolitec Unternehmensbeteiligungs Ii Ag filed Critical Ceramoptec Ind Inc
Publication of BRPI0714667A2 publication Critical patent/BRPI0714667A2/pt
Publication of BRPI0714667A8 publication Critical patent/BRPI0714667A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

CONJUGADO MOLECULAR E RESPECTIVO USO. São proporcionados conjugados moleculares antimicrobianos para o tratamento e prevenção de doenças infecciosas causadas por microorganismos patogênicos em pessoas humanas e animais. A chave para estes conjugados é um espaçador especial que conecta pelo menos um fotossensibilizador a um receptor de microorganismo(vetor) que, por sua vez, se liga seletivamente à superfície de um microorganismo provocando a fotodestruição por irradiação. Os espaçadores de estrutura hidrofílica tal como unidades de etilenoglicol e unidades de etilenoglicol revestidas no término por amino carboxil devem ser usados para ligar o vetor ao fotossensibilizador. Numa modalidade preferida, um espaçador teria pelo menos 3 unidades de etilenoglicol e seria revestido no término com um grupo carboxil e um grupo amino no outro término. A presente invenção funciona efetivamente para combater a infecção bacteriana nos ambientes reais relacionados com pacientes em que o sangue, soro e outros fluidos de corpo estão sempre presentes ou pelo menos na vizinhança. Os espaçadores de comprimento e estrutura selecionados, em modalidades preferidas, são usados para ligar o vetor ao fotossensibilizador. Estes conjugados são constatados serem muito efetivos no combate à infecção bacteriana nos ambientes reais relacionados com pacientes em que o sangue, o soro e outros fluidos de corpo estão sempre presentes ou pelo menos na vizinhança. É também proporcionado um método de uso.
BRPI0714667A 2006-07-27 2007-07-27 Conjugado molecular e respectivo uso BRPI0714667A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US60833,836 2006-07-27
US11880974 2007-07-25
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
PCT/US2007/016951 WO2009014524A2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Publications (2)

Publication Number Publication Date
BRPI0714667A2 BRPI0714667A2 (pt) 2013-08-06
BRPI0714667A8 true BRPI0714667A8 (pt) 2016-10-18

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714667A BRPI0714667A8 (pt) 2006-07-27 2007-07-27 Conjugado molecular e respectivo uso

Country Status (4)

Country Link
EP (1) EP2049105A4 (pt)
BR (1) BRPI0714667A8 (pt)
MX (1) MX2009001074A (pt)
WO (1) WO2009014524A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001416A (es) * 2019-08-02 2022-05-26 Koite Health Oy Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente.
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Also Published As

Publication number Publication date
EP2049105A2 (en) 2009-04-22
WO2009014524A2 (en) 2009-01-29
WO2009014524A3 (en) 2020-10-15
MX2009001074A (es) 2009-06-05
EP2049105A4 (en) 2022-03-30
BRPI0714667A2 (pt) 2013-08-06

Similar Documents

Publication Publication Date Title
Evren et al. In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin
Maksymowych et al. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade
Charrier et al. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis
Azman et al. Actinobacteria—a promising natural source of anti-biofilm agents
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
Descourouez et al. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
RU2412710C2 (ru) Применение тилвалосина в качестве противовирусного агента
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
Zhou et al. Pterostilbene, a potential MCR-1 inhibitor that enhances the efficacy of polymyxin B
BRPI0411016A (pt) composições antisépticas, processos e sistemas
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0016709A (pt) Agente antiadesão da flora patogênica da pele
BRPI0519135A2 (pt) macrolÍdeos
BR9711843A (pt) Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos
DE69932733D1 (de) Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
BR112019009953A2 (pt) substâncias direcionadas a vários órgãos ou tecidos selecionados
Kunz Coyne et al. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms
Smith et al. The effect of cell-free fluids prepared from cultures of human and animal enteropathogenic strains of Escherichia coli on ligated intestinal segments of rabbits and pigs
Karau et al. Exebacase in addition to daptomycin is more active than daptomycin or exebacase alone in methicillin-resistant Staphylococcus aureus osteomyelitis in rats
BR0308316A (pt) Sais de nateglinida
BR0210798A (pt) vacinas de mycoplasma bovis e métodos de redução de pneumonia em animais
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BRPI0714667A8 (pt) Conjugado molecular e respectivo uso
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOLITEC PHARMA MARKETING LTD. (MY)

B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]